Display Settings:

Format

Send to:

Choose Destination
Oncol Rep. 1997 Jul-Aug;4(4):723-7.

Hydroxyurea as a modulator of multidrug resistance in resistant solid tumor.

Author information

  • 1UNIV PALERMO,INST CLIN MED,I-90127 PALERMO,ITALY. UNIV PALERMO,MED ONCOL SERV,I-90127 PALERMO,ITALY.

Abstract

We enrolled 11 consecutive pre-treated resistant advanced cancer patients to receive hydroxyurea (HU) (as modulator of MDR) 10 mg/kg/day (d) p.o. d 1-14 in association with DXR (d 15) alone or in combination with VDS (d 15) or VP16 (d 15-17) in presence, respectively, of soft tissue sarcoma, breast carcinoma, lung and gastric carcinoma. We obtained a stabilization of disease (NC) in 62.5% of patients, with a mean duration of 6 months. The mean survival was 12.2+ months for NC and 6 months for progressive disease (PD). No severe or unexpected adverse events were reported over 34 cycles administered; the most frequently recorded side effects were haematological and gastrointestinal toxicity. It seems that at the dosage we used, HU is poorly active in overcoming MDR; further studies with larger number of patients and different dosage are needed.

PMID:
21590128
[PubMed]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Spandidos Publications
    Loading ...
    Write to the Help Desk